Fred Zheng
Incyte Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fred Zheng as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:49 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03688152 · A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaIncyte Corporation · completed · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma · study director
- Ph1NCT03514407 · A Study of INCB059872 in Relapsed or Refractory Ewing SarcomaIncyte Corporation · terminated · Relapsed Ewing Sarcoma · study director
- Ph2NCT03235544 · A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorIncyte Corporation · completed · Lymphoma · study director
- Ph2NCT03144674 · A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)Incyte Corporation · completed · Lymphoma · study director
- Ph2NCT03126019 · A Study of INCB050465 in Relapsed or Refractory Follicular LymphomaIncyte Corporation · completed · Lymphoma · study director
- Ph1/Ph2NCT03085914 · A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)Incyte Corporation · completed · Solid Tumor · study director
- Ph1/Ph2NCT02712905 · An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesIncyte Corporation · terminated · Solid Tumors and Hematologic Malignancy · study director
- Ph1/Ph2NCT02711137 · Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte Corporation · terminated · Solid Tumors · study director
- Ph1/Ph2NCT02587598 · Study of INCB053914 in Subjects With Advanced MalignanciesIncyte Corporation · terminated · Solid Tumors · study director
- Ph1/Ph2NCT02431260 · An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesIncyte Corporation · terminated · Solid Tumors and Hematologic Malignancy · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:49 UTC. The ranking covers the 200 most relevant of 83 PubMed records, and a shared surname and initials can bring in a namesake. All 83 on PubMed
- 432 citationsRCR 13.5
- NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis.Heart Lung Circ · 2013153 citationsRCR 4.5
- Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.J Natl Cancer Inst · 2020131 citationsRCR 7.1
- 119 citationsRCR 2.6
- 83 citationsRCR 3.7
- Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.Lancet Infect Dis · 202277 citationsRCR 6.5
- Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.Clin Cancer Res · 202069 citationsRCR 2.5
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).Eur J Cancer · 201666 citationsRCR 1.8
- Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.J Nucl Med · 201065 citationsRCR 2.0
- Effects of an Outpatient Diabetes Self-Management Education on Patients with Type 2 Diabetes in China: A Randomized Controlled Trial.J Diabetes Res · 201957 citationsRCR 4.3